國家衛生研究院 NHRI:Items for Author

Year

Loading year class tree, please wait....

Collection	Date	Title	Relation
[陳立宗] 會議論文/會議摘要	2018-10	Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV): Survival analysis from NAPOLI-1	-
[陳立宗] 會議論文/會議摘要	2018-06	The effect of best response to prior anticancer therapy on efficacy outcomes in the napoli-1 trial of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy	-
[陳立宗] 會議論文/會議摘要	2018-06	Decreased appetite (DA) at baseline impacts prognosis in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC)	-
[陳立宗] 會議論文/會議摘要	2018-06	Prognostic effect of primary tumor location in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC)	-
[陳立宗] 會議論文/會議摘要	2018-06	Prognostic value of baseline biliary stents on outcomes in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the NAPOLI-1 trial	-
[陳立宗] 會議論文/會議摘要	2016-09	Effects of nanoliposomal irinotecan (nal-IRI; MM-398) +/- 5-fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy: Results from t	-